Unlocking
the future
of medicine

About us

Offering an unrivalled modular platform and tailored hyper-targeting is how we stand apart

Pipeline

Reducing the impact of cancer and infectious diseases on people’s lives is why we’re here

Innovation and research

Pushing the boundaries of human advancement in medicine is what drives us every day

Investors
 
 
 

A vaccine platform that unlocks unlimited possibilities for the future of medicine

The Nykode Therapeutics platform is built around the Vaccibody molecule. Inducing fast, strong and long-lasting immune responses, and demonstrating a positive safety profile, our pioneering Vaccibody™ vaccine has the potential to treat many disease areas, including cancer.

Highlights

Minutes of Extraordinary General Meeting

Read More
30 November 2021

Nykode Therapeutics (formerly Vaccibody*)) resolves to issue shares to ...

Read More
24 November 2021

ABGSC Oncology Seminar

Read More
23 November 2021

Nykode Therapeutics company update

Read More
23 November 2021

Nykode Therapeutics (formerly Vaccibody) enters into multi-target license and ...

Read More
23 November 2021

Vaccibody becomes Nykode Therapeutics

Read More
23 November 2021

Vaccibody AS – Notice of Extraordinary General Meeting

Read More
23 November 2021

Vaccibody to participate at Jefferies London Healthcare Conference

Read More
10 November 2021

Vaccibody announces first subject dosed in a two-arm phase ...

Read More
03 November 2021